Category: Diabetes and other autoimmune endocrine diseases

F.87 - Type 1 Diabetes Is an Immunologically Heterogeneous Disease: Findings from a Longitudinal Study of cd4 and cd8 Cell Autoimmune Variation

Friday, Jun 16
6:15 PM – 7:30 PM

Craig Beam

Research Professor
University of Western Michigan
Kalamazoo, Michigan

Mark Peakman

Professor of Clinical Immunology
Peter Gorer Department of Immunobiology, Kings College London
London, England, United Kingdom

Mark Peakman trained in medicine at University College London and pursued postgraduate training in clinical immunology. After he received his PhD based on studies of the immune system in Type 1 diabetes (a childhood disease in which the cells that make insulin in the body are irreparably damaged by inflammation) he held a senior clinical research fellowship at the University of Pittsburgh. He subsequently returned to the UK and now oversees a research group at King’s College London in the Department of Immunobiology. The main focus of the research is the role of immune cells (T lymphocytes) in the aetiology of the autoimmune disease, Type 1 diabetes. In particular, the group has defined the critical targets for T cells that appear to have a role in the destruction of insulin-producing cells, and key immunological pathways through which this damage is mediated. More recently, the work has led to the definition of targets enabling the design of a novel approach to therapy. This strategy, termed “peptide immunotherapy” is the first of its kind in diabetes and further phases of this programme are ongoing. In the future, a better understanding of the role of the immune response in Type 1 diabetes will promote the further development of these novel therapeutics into the clinical setting.

Lorraine Yeo

Peter Gorer Department of Immunobiology, Kings College London
London, England, United Kingdom

Alyssa Woodwyk

Western Michigan University Homer Stryker M.D. School of Medicine
Kalamazoo, Michigan